Fifth Third Wealth Advisors’s Boston Scientific BSX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.74M Sell
40,756
-12,343
-23% -$670K 0.05% 222
2026
Q1
$3.33M Buy
53,099
+2,712
+5% +$217K 0.11% 144
2025
Q4
$4.8M Sell
50,387
-2,069
-4% -$203K 0.17% 99
2025
Q3
$5.12M Buy
52,456
+1,323
+3% +$137K 0.19% 91
2025
Q2
$5.49M Buy
51,133
+13,818
+37% +$1.4M 0.23% 74
2025
Q1
$3.76M Buy
37,315
+5,566
+18% +$560K 0.2% 84
2024
Q4
$2.84M Buy
31,749
+3,204
+11% +$282K 0.15% 96
2024
Q3
$2.39M Sell
28,545
-276
-1% -$21.8K 0.15% 103
2024
Q2
$2.22M Buy
28,821
+13,345
+86% +$977K 0.17% 83
2024
Q1
$1.06M Sell
15,476
-1,479
-9% -$95.1K 0.17% 98
2023
Q4
$980K Sell
16,955
-4,050
-19% -$216K 0.32% 72
2023
Q3
$1.11M Buy
21,005
+3,810
+22% +$200K 0.45% 59
2023
Q2
$930K Buy
+17,195
New +$898K 0.6% 46

Other funds holding BSX

Fifth Third Wealth Advisors's BSX Position: Q2 2026 in Review

Fifth Third Wealth Advisors reduced its Boston Scientific (BSX) stake by 23% in Q2 2026, selling an estimated $670K and leaving 40,756 shares worth $1.74M. The position accounts for 0.05% of the portfolio, ranked #222.

Fifth Third Wealth Advisors first reported a position in BSX in Q2 2023 and has held it in 13 quarters since. The position peaked at $5.49M in Q2 2025. 189 funds tracked by Wall St. Rank hold BSX as of Q2 2026.

  • Fifth Third Wealth Advisors held 40,756 shares of Boston Scientific worth $1.74M as of Q2 2026.
  • Fifth Third Wealth Advisors sold 12,343 Boston Scientific shares in Q2 2026, an estimated $670K.
  • Boston Scientific made up 0.05% of Fifth Third Wealth Advisors's portfolio in Q2 2026, its #222 holding.
  • Fifth Third Wealth Advisors first reported a position in Boston Scientific in Q2 2023 and has held it in 13 quarters since.
  • Fifth Third Wealth Advisors's Boston Scientific position peaked at $5.49M in Q2 2025.
  • 189 funds tracked by Wall St. Rank held Boston Scientific as of Q2 2026.

Based on Fifth Third Wealth Advisors's 13F filing for Q2 2026, filed 17 Jul 2026.